7th IPF Summit
When:
Tuesday, Sep 19, 2023 9:00a -
Thursday, Sep 21, 2023 4:00p
Tuesday, Sep 19, 2023 9:00a -
Thursday, Sep 21, 2023 4:00p
Where:
Revere Hotel Boston Common
200 Stuart Street
Boston, Massachusetts 02116
Admission:
$5297.00
Hosted by:
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/1778010-0?pid=5248
With Nintedanib and Pirfenidone set to lose their patents in the next 3-6 years, Pliant Therapeutics moving into phase 2b, readouts expected from FibroGen's phase 3 trial and Galecto's phase 2 study and Bristol Myers Squibb's and Boehringer Ingelheim's clinical trials both well under way...the race is on to advance the next generation of IPF drugs and beat the benchmark set by the standard of care.
We're at the precipice of hailing disease-modifying IPF drugs to patients with the increasing understanding of lung pathobiology and cell cross talk using multi-omic approaches expanding the horizons of therapeutic targets to slow, halt, reverse and regenerate progressively fibrosing lung tissue. Imaging and AI are being harnessed more than ever to show therapeutic efficacy beyond lung function and clinical trials are being designed to be more effective and swifter.
The 7th IPF Summit is the undisputed, comprehensive, end-to-end, 3-day conference for you and your team to grasp the latest readouts and take new insights back to your therapeutic development. Don't miss this opportunity to discuss the latest unpublished data and network with 180+ movers and shakers in the pulmonary fibrosis field.
URLs:
Tickets: https://go.evvnt.com/1778010-2?pid=5248
Brochure: https://go.evvnt.com/1778010-3?pid=5248
Prices:
Drug Developer - Conference + Seminar Day: USD 4297.00,
Drug Developer - Conference Only: USD 2999.00,
Solution Provider - Conference + Seminar Day: USD 5297.00,
Solution Provider - Conference Only: USD 3799.00,
Academic Pricing - Conference + Seminar Day: USD 3697.00,
Academic Pricing - Conference Only: USD 2599.00
Speakers: Andrew Thorley, Director, Principal Scientist and Group Leader - Nephrology and Chronic Obstructive Pulmonary Disease and Biomarker Development, Genentech, Bertil Lindmark, Chief Medical Officer, Galecto Biotech, Caroline Owen, Executive Director - Medical Early Clinical Development, Respiratory and Immunology, AstraZeneca, Cathy Swindlehurst, Chief Executive Officer, NovoMedix, Christina Kalderén, Preclinical director, Oxcia, David Lederer, Executive Medical Director, Early Clinical Development and Experimental Sciences, Regeneron, David Salzman, Founder and Chief Executive Officer, GATEHOUSE BIO, Elizabeth Redente, Associate Professor, National Jewish Health, Eric Lefebvre, Chief Medical Officer, Pliant Therapeutics Inc., Eric White, Senior Lead - Clinical Program and Interstitial lung disease, Boehringer Ingelheim, Fernando Martinez, Professor - Internal Medicine, Weill Cornell Medical College, Gary Matt Hunninghake, Assistant Professor, Brigham and Women's Hospital at Harvard Medical School, Gisli Jenkins, Chair and Professor - Research and Margaret Turner Warwick Thoracic Medicine, Imperial College, London, Hans Brightbill, Senior Manager - Scientific and Translational Immunology and Fibrosis Disease Area Strategy Lead, Genentech, Hans-Willem Snoeck, Professor - Medicine, Microbiology and Immunology, Columbia University, Jessica Shore, Vice President of Clinical Affairs and Quality, Pulmonary Fibrosis Foundation, Joyce Lee Associate, Professor - Medicine-Pulmonary Sciences and Critical Care, University of Colorado Anschutz Medical Campus, Justin Oldham, Associate Professor, University of Michigan, Ke Cheng, Professor, Founder (BreStem Therapeutics), NC State University, Kevin Hart, Director and Associate Fellow - Scientific and Research, Pfizer, Lee Borthwick, Chief Operating Officer and Director, FibroFind, Lyn Barinowski, Chief Executive Officer, Avalyn Pharmaceuticals, Mahboobe Ghaedi, Lead Principle Scientist - Respiratory and Inflammation, AstraZeneca, Mark Eisner, Executive Vice President and Chief Medical Officer, FibroGen, Matthew Moll, Instructor in Medicine, Brigham and Women's Hospital at Harvard Medical School, Muhunthan Thillai, Director, Qureight, Muriel Lize, Associate Director - In Vitro Respiratory Research, Boehringer Ingelheim, Naftali Kaminski, Professor and Chief Of Medicine, Section Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, Peter George, Consultant and Clinical Lead Royal Brompton and Harefield, NHS Trust, Philip Zach Brohawn, Head of Biomarker Discovery, AstraZeneca, Rahul Ballal, Chief Executive Officer, Mediar Therapeutics, Robin Mansukhani, Chief Executive Officer, Deciduous Therapeutics, Rohit Batta, Chief Medical Officer, Vicore Pharma Holding, Simon Walsh, Clinician Scientist, Imperial College London, Steven Greenberg, Executive Director - Inflammation and Immunology, Bristol Myers Squibb, Sudha Visvanathan, Vice President, Global Head of Theraputic Area Inflammation, Boehringer Ingelheim, Sunhwa Kim, Associate Scientific Director, Abbvie, Timothy Watkins, Vice President and Head, Fibrosis and Pulmonary Diseases and Inflammation, Gilead Sciences, Toby Maher, Clinical Instructor, University of Southern California, Vanessa Neiens, Biology Lead Respiratory, Pieris Pharmaceuticals
-
Sponsored -
Sponsored -
SponsoredJuegos de Palabras: Spanish game night at BASE
Tuesday, Nov 19, 2024 6:00p
Boston Area Spanish Exchange (BASE)
